The study of three-dimensional dosimetric verification of volumetric-modulated arc therapy for nasopharyngeal carcinoma based on ArcCHECK-3DVH system(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2020年第12期
- Page:
- 1506-1512
- Research Field:
- 医学放射物理
- Publishing date:
Info
- Title:
- The study of three-dimensional dosimetric verification of volumetric-modulated arc therapy for nasopharyngeal carcinoma based on ArcCHECK-3DVH system
- Author(s):
- YANG Lu; YU Hui; ZHANG Guoqian; ZHANG Quanbin; ZHANG Shuxu
- Radiotherapy Center, Cancer Center of Guangzhou Medical University, Guangzhou 510095, China
- Keywords:
- ArcCHECK 3DVH nasopharyngeal carcinoma volumetric-modulated arc therapy three-dimensional dosimetric verification
- PACS:
- R815.6；R739.6
- DOI:
- DOI:10.3969/j.issn.1005-202X.2020.12.007
- Abstract:
- Objective To investigate the application of ArcCHECK-3DVH system in three-dimensional dosimetric verification of volumetric-modulated arc therapy (VMAT) for nasopharyngeal carcinoma (NPC). Methods 20 WMAT treatment plans based on Monaco Treatment Planning System (TPS) for NPC have been selected to perform the dosimetric verification by using the ArcCHECK-3DVH system. The 3D γ-pass rates of the TPS dose calculation and ArcCHECK-3DVH system dose reconstruction have been comparatively analyzed with the criteria of 3 mm/3%, TH=10%, and their dose parameters for target volumes and organs at risk (OAR), such as D98%, D2%, Dmax, Dmean were also compared. Results The 3D γ-pass rate of treatment plans was 98.20% (97.75%, 99.20%), and the difference in parameters for target volumes D98%, D2%, Dmean between the TPS calculation dose and the ArcCHECK-3DVH dose reconstruction were mostly less than 3%, with a maximum difference of less than 5% in some individual cases. For most patients, the γ-pass rate for the whole target organs, except PGTVnd, were higher than 90%. Their difference in parameters for organs at risk (OAR) Dmax and Dmean were less than 6% and the γ-pass rates for OAR were above 93%. Conclusions The reconstruction doses by the ArcCHECK-3DVH system were in good agreement with the TPS calculation doses, which provide multiple parameters for the dose verification of VMAT plan for nasopharyngeal carcinoma, and can help the quality assurance of treatment plans.
Last Update: 2020-12-30